Oridonin acts as a novel senolytic by targeting glutathione S-transferases to activate the ROS-p38 signaling axis in senescent cells

Authors:

Abstract
Most of the known senolytics are anti-cancer drugs or their derivative molecules. However, senolytics derived from the active ingredients of traditional Chinese medicine (TCM) are rarely reported. Here, we identified oridonin as a novel senolytic and further revealed that it might target a class of glutathione S-transferases to activate ROS-p38 signaling and induce apoptosis in senescent cells.
Funding Information
  • National Key Research and Development Program of China (2020YFA0908000)
  • State Administration of Traditional Chinese Medicine of the People's Republic of China (ZYYCXTD-C- 202002)
  • National Science and Technology Infrastructure Program (2020YFE0205100)
  • China Academy of Chinese Medical Sciences (CI2021A05101, CI2021A05104)
  • Fundamental Research Funds for the Central Universities (ZZ15-YQ-062)
  • National Natural Science Foundation of China (82074098, 81841001, 82274182)

This publication has 22 references indexed in Scilit: